Form 4: Rigel Pharma EVP Sells Shares for Tax Obligations

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A Santos, disposed of 3,546 shares of common stock to cover tax liabilities.

Summary

• David A Santos, Executive Vice President and Chief Commercial Officer of Rigel Pharmaceuticals, Inc. (RIGL), reported a transaction on February 10, 2026.
• The transaction involved the disposition of 3,546 shares of common stock.
• The shares were disposed of at a price of $34.62 per share.
• This disposition was made under transaction code 'F', indicating it was for the payment of tax liability by delivering or withholding securities incident to the receipt, exercise, or vesting of a security.
• Following this transaction, Mr. Santos beneficially owns 43,440 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction code 'F' indicates a non-discretionary sale for tax purposes, which is a routine part of executive compensation and does not typically signal a change in company fundamentals or management's confidence.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, such as dispositions for tax withholding purposes, are common in the biotechnology and pharmaceutical sectors as part of executive compensation plans. These types of transactions typically do not reflect a change in management's outlook on the company's future performance or broader industry trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not reflect a change in the company's operational or financial outlook.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax liabilities associated with compensation. Such transactions are common and generally do not provide new information that would warrant a change in investment recommendation. The core investment thesis for Rigel Pharmaceuticals remains unchanged based solely on this filing.

Keywords

Rigel Pharmaceuticals, RIGL, David A Santos, Insider Transaction, Form 4, Stock Sale, Tax Withholding, Executive Compensation